
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular Inc. demonstrated a positive financial outlook, evidenced by a gross margin expansion of 110 basis points year-over-year to 70%, attributed to higher average selling prices, manufacturing efficiencies, and an advantageous product mix. In the latest quarter, operating income increased by 12% year-over-year to $16.1 million, resulting in an operating margin of 25%, while revenues grew by 15% both as reported and organically. Furthermore, the company's net income rose by 17% to $13.8 million, and diluted earnings per share reached $0.60, indicating solid growth potential and a strong trajectory for the future.
Bears say
LeMaitre Vascular Inc is facing a negative financial outlook primarily due to a projected decline in operating margin, anticipated to fall to 24% from 25% as a result of seasonal fluctuations. The company has also revised its target for the number of sales representatives downward, from 170 to 165, which could hinder revenue growth. Additionally, a decrease in R&D expenditure to 6% of revenue raises concerns about product innovation and could adversely affect the firm's competitive position amidst regulatory challenges and slower international market adoption.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares